Robert L. Coleman, MD | Authors

June 15, 2021

Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.

February 04, 2021

Therapies targeting oncogenesis and the tumor microenvironment are increasingly replacing chemotherapies as first-line treatments for non–small cell lung cancer.

October 25, 2020

Much is still unknown about the cancer process and how targeted therapies work on specific tumor vulnerabilities. Providers must closely follow evolving information, especially regarding adverse events.

September 21, 2020

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

October 08, 2019

Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.

August 18, 2015

Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.